JP2022517433A5 - - Google Patents

Info

Publication number
JP2022517433A5
JP2022517433A5 JP2021541666A JP2021541666A JP2022517433A5 JP 2022517433 A5 JP2022517433 A5 JP 2022517433A5 JP 2021541666 A JP2021541666 A JP 2021541666A JP 2021541666 A JP2021541666 A JP 2021541666A JP 2022517433 A5 JP2022517433 A5 JP 2022517433A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weight
cgrp antagonist
breakthrough
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021541666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022517433A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014239 external-priority patent/WO2020150703A1/en
Publication of JP2022517433A publication Critical patent/JP2022517433A/ja
Publication of JP2022517433A5 publication Critical patent/JP2022517433A5/ja
Pending legal-status Critical Current

Links

JP2021541666A 2019-01-20 2020-01-19 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト Pending JP2022517433A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962794665P 2019-01-20 2019-01-20
US62/794,665 2019-01-20
US201962844169P 2019-05-07 2019-05-07
US62/844,169 2019-05-07
US201962893206P 2019-08-29 2019-08-29
US62/893,206 2019-08-29
US201962910284P 2019-10-03 2019-10-03
US62/910,284 2019-10-03
US202062959088P 2020-01-09 2020-01-09
US62/959,088 2020-01-09
PCT/US2020/014239 WO2020150703A1 (en) 2019-01-20 2020-01-19 Cgrp antagonists for treating migraine breakthrough

Publications (2)

Publication Number Publication Date
JP2022517433A JP2022517433A (ja) 2022-03-08
JP2022517433A5 true JP2022517433A5 (https=) 2022-09-22

Family

ID=71613964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021541666A Pending JP2022517433A (ja) 2019-01-20 2020-01-19 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト

Country Status (13)

Country Link
US (2) US20210338654A1 (https=)
EP (1) EP3911409A4 (https=)
JP (1) JP2022517433A (https=)
KR (1) KR20210116560A (https=)
CN (1) CN113316470A (https=)
AU (1) AU2020210024A1 (https=)
BR (1) BR112021011546A2 (https=)
CA (1) CA3127328A1 (https=)
IL (1) IL284947A (https=)
MX (1) MX2021008191A (https=)
PH (1) PH12021551689A1 (https=)
SG (1) SG11202106721VA (https=)
WO (1) WO2020150703A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202535450A (zh) * 2018-07-05 2025-09-16 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法
US20210121541A1 (en) * 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
WO2021055769A1 (en) 2019-09-18 2021-03-25 Massachusetts Institute Of Technology Systems, compositions, and methods for producing sharp edges
WO2021062282A1 (en) * 2019-09-25 2021-04-01 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
WO2022109077A1 (en) * 2020-11-19 2022-05-27 Biohaven Pharmaceutical Holding Company Ltd. Compositions for improved delivery of cgrp inhibitors
IT202000029459A1 (it) * 2020-12-03 2022-06-03 Alberto Chiarugi Terapia dei disturbi emotivi
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
US20240408080A1 (en) * 2021-02-01 2024-12-12 Pfizer Ireland Pharmaceuticals Pharmaceutical compositions of cgrp inhibitors and methods of their use
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
WO2023064195A1 (en) * 2021-10-11 2023-04-20 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating trigeminal neuralgia
CN114053232A (zh) * 2021-11-23 2022-02-18 莱默(北京)药业科技有限公司 一种乌布吉泮冻干口崩片及制备方法
WO2023177823A1 (en) * 2022-03-17 2023-09-21 Vasoceuticals, Inc. Combined use of individual compounds for treatment of chronic pain disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908014D0 (en) * 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
US8481546B2 (en) * 2010-03-30 2013-07-09 Bristol-Myers Squibb Company CGRP receptor antagonist
HUE047050T2 (hu) * 2012-02-27 2020-04-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só
CN109952314A (zh) * 2016-09-23 2019-06-28 泰瓦制药国际有限公司 治疗难治性偏头痛
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
MX2020009856A (es) * 2018-03-25 2020-10-08 Biohaven Pharm Holding Co Ltd Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TW202535450A (zh) * 2018-07-05 2025-09-16 愛爾蘭商歐樂根製藥國際有限公司 Cgrp拮抗劑及梭菌衍生物之組合療法

Similar Documents

Publication Publication Date Title
JP2022517433A5 (https=)
US20170216212A1 (en) Tapentadol compositions
JP6117845B2 (ja) ニタゾキサニドの制御放出医薬配合物
US20080026054A1 (en) Novel anelgesic combination
CN1681486A (zh) 莫达非尼药物剂型
JP2012021025A (ja) メロキシカムを含む組成物
JP2022516662A5 (https=)
FR2889811A1 (fr) Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
BG102669A (bg) Метод за лечение и фармацевтичен състав
US20210196685A1 (en) Composition for eradicating helicobacter pylori
CN1291092A (zh) 含有曲马朵的药物组合物
WO2005094832A1 (en) Compositions comprising meloxicam
US20050038018A1 (en) Meloxicam compositions
EP3432931A1 (en) Pharmaceutical compositons for n-propargylamine derivative
CN101360756A (zh) 治疗胃肠道病症的方法和组合物
KR102496504B1 (ko) 남성 피임을 위한 비호르몬 조성물 및 방법
JP2009535336A (ja) 片頭痛治療用の固定組合せ剤形
CN112263581A (zh) 一种治疗pe和ed的双层片复方制剂及其制备方法
Çetin Fixed-dose combination-orally disintegrating tablet (FDC-ODT) studies for the treatment of type 2 diabetes or cardiovascular diseases-a mini review
HK1047547A1 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
CN115887462A (zh) 一种口服药物组合物
RU2025133530A (ru) Лечение бокового амиотрофического склероза (бас)
WO2017100324A1 (en) Combination therapy for treating female hypoactive sexual desire disorders
CN101277683A (zh) 普那卡生的延迟制剂
CN1832758A (zh) 药物组合物